Hooman Kamel, M.D., M.S.

Dr. Kamel is the Helen and Albert Moon Professor, Chief of Neurocritical Care, and Vice Chair for Research in the Department of Neurology at Weill Cornell Medicine. He also directs the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. Dr. Kamel attended college at Harvard and medical school at Columbia, then trained as a neurology resident and neurocritical care fellow at UCSF before joining Weill Cornell Medicine in 2011. He has published over 450 scientific papers, including in leading journals such as NEJM and JAMA. He was a principal investigator for the NIH-funded ARCADIA trial, which tested antithrombotic strategies in patients with stroke and atrial cardiopathy. He is also a principal investigator of the NIH-funded ASPIRE trial, which is testing antithrombotic strategies in patients with atrial fibrillation and intracerebral hemorrhage. He serves on the NIH StrokeNet Executive Committee and chairs its Prevention Working Group, and he serves on the leadership committees of several multicenter randomized trials, including STROKE-AF, Librexia AF, REACT-AF, and LAAOS-4. He is the Deputy Editor of JAMA Neurology and an editorial board member of Stroke. His academic contributions have been recognized by the Michael S. Pessin Stroke Leadership Prize from the American Academy of Neurology, and the Robert G. Siekert New Investigator Award in Stroke, the Joseph A. Vita Award, and the Stroke Council Award from the American Heart Association.